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949FO-5 Angiotensin Converting Enzyme Inhibition Reduces 
Elevated C-Reactive Protein in Patients With 
Angiographic Coronary Artery Disease 
Chloe A. Allen Maycock. Joseph B. Muhlestein, Benjamin D. Home, Robert R. Pearson, 
Tami L. Bair, Tobin H. Lim, Heath U. Jones, Sandra P. Reyna, Stephanie V. Moore, Dale 
G. Renlund, Jeffrey L. Anderson. LDS Hospital, Salt Lake City, UT, University of Utah, 
Salt Lake City, UT 
Background: lnflammatron is hypothesized to play a role in all stages of atherosclerosis, 
and C-reactive protein (CRP), a marker of inflammation, is associated with greater car- 
diovascular risk. The inflammatory process is upregulated by the renin-angiotensin sys- 
tem @AS), which suggests that inhibition of the RAS may affect CRP expression. The 
objective of this study was to determine if angiotensin converting enzyme inhibition 
(ACEI) or angiotensin receptor blockade (ARB) reduces high-sensitivity (hs)CRP con- 
centrations fn a large prospective cohort undergoing coronary angiography. 
Methods Baseline blood samples and patient histories were obtained from 507 patients 
(pts) not receiving ACEI or ARB who were hospitalized for coronary angiography; 71% 
had significant (270%) CAD. After an average follow-up period of 3 years (range: 2 to 4 
years), repeat blood samples and recent medical histories were obtained, including any 
initiation of ACEI or ARE. Hs-CRP was measured (Dada Behring) at baseline and at last 
follow-up (z-2 years). Potential confounders (age, smoking history, gender, and beta- 
blocker, aspirin, and/or statin therapies) were examined together with hsCRP in multivari- 
able regression. 
Results 116 subjects (mean age: 64+11 years, 74% male) reponed ACEI use, 36 pts 
(mean age: 67~10 y. 66% male) reported ARB use, and 351 (mean age: 66*10 y. 66% 
male) reported neither. Median hsCRP at baseline was 0.21 mg/dL (range: 0.02-15 ms/ 
dL). Pts taking ACEI experienced a greater hsCRP reduction than non-ACEllnon-ARB 
controls (median change: -0.05 mg/dL vs 0.0 mg/dL; p=O.OOS). A trend in hsCRP reduc- 
tion for the smaller ARB groups was not significant (median change: -0.03 mg/dL vs 0.0 
mg/dL; p=NS). In multivariable regression, only ACEI therapy (p=O.O07) and statin ther- 
apy (p=O.O34) were selected as independent predictors of hsCRP change. 
Conclusion: In a coronary high-risk cohort, initiation of ACEI significantly and indepen- 
dently reduced plasma hsCRP. even after controlling for statin therapy and other con- 
founders. A vascular anti-inflammatory effect may represent an additional mechanism by 
which ACEI are associated with benefit to patients with or at risk for CAD. 
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B49FO-6 A Risk Score for Predicting Coronary Artery Bypass 
Surgery in Patients With Non-ST Elevation Acute 
Coronary Syndromes 
Saihari Sadanandan Christopher P. Cannon, C. Michael Gibson, Rajen Desaf, Sabina A. 
Murphy, Peter M. DiBattrste, Eugene Braunwald. for the TACTICS TIMI- Investigators, 
Brigham & Women’s Hospital, Boston, MA 
Background: Routine early use of clopidogrel in patients with unstable angina/non-ST 
elevation myocardial infarction (UAMSTEMI) undergoing early coronary artery bypass 
surgery (CABG) IS associated with increased risk of pen-operative bleeding. A simple 
clinical risk score on admission to predict the likelihood of CABG during index hospital- 
ization in such patients might be useful. 
Methods: We evaluated 2220 patients with UA4NSTEMI randomized to early invasive 
(INV) or conservative (CON) strategy in the TACTICS TIMI- trial. Patients with h/o prior 
CABG (n=484) were significantly less likely to undergo in-hospital CABG (OR 0.34, 
p<O.OOOl) and they were excluded. A logistic regression model was developed to identffy 
clinical variables independently assocrated with CABG. A p-value of co.05 was reqwed 
for retention in the model. The model was validated using UA/NSTEMI patient population 
from TIMI 118 (N=3229) and TIMI 3B (N=694) trials. 
Results: Of the 1736 patients studied, 326 (18.6%) underwent CABG following index 
hospitalization. The median time to CABG in the overall population was 3.6 days (2.5, 
6.0); INV pts 3.4 days (1.9, 4.9) and CON pts 5.0 days (3.7, 7.9). We identified 6 vari- 
ables independently associated with CABG; (+) tn T or I (OR 4.3). h/o peripheral vascular 
disease (OR 2.0) ST segment deviatron >0.5mm (OR 1.6) prior h/o stable angina (OR 
1.7) male gender (OR 1.6) prior aspirin use (OR 1.4) and hyperlipidemia (OR 1.4). A 
risk score was generated by assfgning a score of 3 for (+) tn T or I and 1 for each other 
variable. The association of the risk score with CABG was hiahlv sianificant (o<O.OOOl. 
C-statistic 0.72). CABG rates increased significantly with increasing risk score (6.6% for 
risk score l-3. 16.4% for 4-6 and 41 .I% for >6.0). The association of the risk score with 
CASG remained significant in the validation model from TIMI 11B (p~O.0001: C-statistic 
0.63) and TIMI 38 (p<O.OOOl; C-statistic 0.65) trials. 
Concfuslon: In patients with UAINSTEMI, a simple risk score based on admfssion cknical 
variables predicts the need for CABG. A risk score > 6.0 is associated with high likeli- 
hood of CABG during index hospitalization. 
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853-l Increased Platelet Receptor Occupancy Following 
Eptifibetide Therapy Is Associated With Improved 
Patency, Tissue Level Perfusion, and ST-Segment 
Resolution in ST-Segment Elevation Myocardlal 
Infarction: An INTEGRITI Substudy 
C. Michael Gibson Lisa K. Jennings, Robert P. Giugliano, Robert A. Harrington. Matthew 
T. Roe, Sabina A. Murphy, Shila Cholera, Kenneth W. Baran, Hans-Peter Hobbach, 
Eugene Braunwald, TIMI Study Group, Boston, MA, University of Tennessee Health 
Science Center, Memphis, TN 
Background: While inhibition of platelet (pit) aggregation is a surrogate measure of drug 
efficacy, the percent of plt glycoprotein (GP)llb-llla receptors occupied by a GPllb-llla 
inhibitor (plt receptor occupancy (RO)) is a more direct and fundamental measure of its 
underlying biologic activity. We hypothesized that improved patency, tissue level perfu- 
sion and ST segment resolution would be associated with hfgher levels of RO. Methods: 
Patients (n=70) treated with low dose TNK + eptifibatide as part of the INTEGRITI study 
were included in the RO substudy. Results: The percent RO at 60 min, as measured by 
D3 mAb binding, was higher among patients with a patent artery (TFG 2/3) at 60 minutes 
after lflic compared with an occluded artery (TFG O/l) (p=O.O05) (Table). The percent 
RO was also higher among patients with normal TIMI Myocardial Perfusion Grade 
(TMPG) 3 compared with incomplete myocardial reperfusron (TMPG O/l/2) (p=O.O4). and 
among patients with complete (>70%) ST resolution compared with incomplete resolu- 
tion (p=O.O05). Conclusions: This study links restoration of epicardial flow, tissue level 
perfusion and ST segment resolution with hrgher levels of plt GPflb-llla receptor occu- 
pancy following therapy with eptifibatide when given in combination with TNK. These 
data provide a pathophysiologic link between plt RO and therapeutic efficacy of combina- 
eon therapy. 
Platelet Receptor Occupancy 
Characteristic Characteristic Present Characteristic Absent P- 
valu 
e 
60 min TFG 2/3 76.2% +I- 9.2%, median 63.9% +I- 29.7%, median 0.00 
77%, n=63 70%, n=7 5 
60 min TMPG 3 79.6% +/- 9.5%, medfan 73.0% +/- 16.2%, median 0.03 
60%, n=40 73%, n=30 6 
Complete (~70%) ST 61.3% +/- 6.3%, median 73.1% +/- 17.4%, median 0.03 
Resolution El%, n=27 74.5%, n=24 4 
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953-2 Clinical Implications of Myocardial Perfusion Status 
Assessed by Myocardial Blush After Primary 
Angioplasty in Acute Myocardial Infarction: Analysis 
From the CADILLAC Trial 
Costantino 0. Costantini, Alexandra J. Lansky. Kazuyuki Shirai, Ecaterina Cristea. 
Cristina Brestowski, Steve Slack, Martin Fahy, Cindy L. Grimes, John D. Carroll, Stuckey 
Thomas, Grulio Guagliumi, Barry Rutherford, Mark Turco. David Math@ Martin B. Leon, 
Gregg W. Stone, Cardiovascular Research Foundation, New York, NY 
Background: Two single center retrospective studies have suggested that myocerdial 
perfusion as assessed by the angiographic blush score is of major prognostic importance 
after primary PCI. The impkcations of myocardial blush grade (MBG) in a randomized 
trial of PCI for AMI have not been reported. 
Methods and Results:ln the CADILLAC trial 2,062 pts of any age with AMf ~12 hours 
without shock were randomized to PTCA + abciximab vs. stenting -+ abciximab. All films 
have been recalled to the angiographic core laboratory for independent blinded evalua- 
tion of blush. Df the 656 films reviewed to date, myocardial penusion was absent or min- 
imal (MBG O/l) in 44% of pts, moderate (MBG 2) in 35%, and normal (MBG 3) in 20%. 
Predictors of reduced blush included male sex (p=O.Ol). LAD location (p<O.OOOl), longer 
time from symptoms onset to first balloon inflation (p=O.Ol). thrombus (p=O.O07), low 
LVEF (p<O.OOOl), and baselme TIMI O/l flow (p=O.0007). Mortality as a function of MBG 
appears in the table. 
All patients MBG O/l 
30 days 3.2% 
1 year 5.9% 
MBG 2 
1.3% 
2.4% 
MBG 3 
0.6% 
2.3% 
P Value 
0.07 
0.03 
